Drug Safety

, Volume 23, Issue 1, pp 77–85 | Cite as

Use of Antifungal Drugs in Pregnancy

A Focus on Safety
Practical Drug Safety


The use of antifungals in pregnancy requires special consideration for the safety of the developing fetus. Clinicians now have an increased repertoire of both topical and systemic antimycotics available to treat superficial or mucotaneous fungal infections including Candida vaginitis. The ability of many nontopical antifungals to penetrate the placenta and achieve measurable, often therapeutic, concentrations in cord blood, fetal tissue and amniotic fluid means that evidence exists of successful treatment of all varieties of systemic fungal disease in pregnant women, even with placental involvement. However, for the same reasons, safety considerations remain a concern.

Although the use of azoles as topical agents for superficial infections is both efficacious and well tolerated, especially when used for short periods, systemic azole therapy is not recommended in pregnancy. Accordingly, amphotericin B remains the drug of choice for systemic, invasive mycotic infections, whether life-threatening or less severe. Unfortunately little if any information is available regarding the safety of the newer lipid formulations of amphotericin B.

There is a general reluctance to perform randomised, comparative studies involving antifungal agents in pregnancy, hence cumulative anecdotal reports form much of the available data; animal studies, although useful, have several drawbacks. There is a need for additional safe and effective new antifungal agents for widespread use in pregnant women.


  1. 1.
    Federal Register. 1980; 44: 37434–67Google Scholar
  2. 2.
    Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152: 924–35PubMedGoogle Scholar
  3. 3.
    Candidosis of the genitalia. Odds FC, editor. Candida and candidosis. A review and bibliography. 2nd ed. London: Bailliere Tindall Publishers, 1988: 124–35Google Scholar
  4. 4.
    Cotch MF, Hillier SL, Gibbs RS, et al. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Am J Ob Gyn 1998; 178: 374CrossRefGoogle Scholar
  5. 5.
    Mazor M, Chaim W, Shinwell ES, et al. Asymptomatic anmiotic fluid invasion with Candida albicans in preterm premature rupture of membranes. Implications for obstetric and neonatal management. Acta Obstet et Gynecol Scand 1993; 72: 52–4CrossRefGoogle Scholar
  6. 6.
    Donders GG, Moerman P, Caudron J, et al. Intrauterine Candida infection: a report of four infected fetuses from two mothers. Eur J Obstet Gynecol Reprod Biol 1991; 38: 233–8PubMedCrossRefGoogle Scholar
  7. 7.
    Shalev E, Battino S, Romano S, et al. Intraamniotic infection with Candida albicans successfully treated with transcervical amnioinfusion of amphotericin. Am J Obstet Gynecol 1994; 170: 1271–2PubMedGoogle Scholar
  8. 8.
    Burns DN, Tuomala R, Chang BH, et al. Vaginal colonization or infection with Candida albicans in HIV-infected women during pregnancy and during the postpartum period. Women and Infants Transmission Study Group. Clin Infect Dis 1997; 24: 201–10PubMedCrossRefGoogle Scholar
  9. 9.
    Catanzaro A. Pulmonary mycosis in pregnant women. Chest 1984; 86Suppl. 3: 145–85Google Scholar
  10. 10.
    Rodrigues J, Niederman MS. Pneumonia complicating pregnancy. Clin Chest Med 1992; 13: 679–91PubMedGoogle Scholar
  11. 11.
    Hager H, Welt SI, Cardasis JP, et al. Disseminated blastomycosis in a pregnant women successfully treated with amphotericin B. J Reprod Med 1988; 33: 485–8PubMedGoogle Scholar
  12. 12.
    Ismail MA, Lerner SA. Disseminated blastomycosis in a pregnant women: review of amphotericin B usage during pregnancy. Am Rev Respir Dis 1982; 126: 350–3PubMedGoogle Scholar
  13. 13.
    Blotta MH, Altemani AN, Amaral E, et al. Placental involvement in paracoccidioidomycosis. J Med Vet Mycol 1993; 31: 249–57PubMedCrossRefGoogle Scholar
  14. 14.
    MacDonald D, Alguire PC. Adult respiratory distress syndrome due to blastomycosis during pregnancy. Chest 1990; 98: 1527–8PubMedCrossRefGoogle Scholar
  15. 15.
    Daniel L, Salit IT. Blastomycosis during pregnancy. Can Med Assoc J 1984; 131: 759–61PubMedGoogle Scholar
  16. 16.
    McGregor JA, Kleinschmidt-DeMasters BK, Ogle J. Meningoencephalitis caused by Histoplasma capsulatum complicating pregnancy. Am J Obstet Gynecol 1986; 154: 925–31PubMedGoogle Scholar
  17. 17.
    Ely EW, Peacock Jr JE, Haponik EF, et al. Cryptococcal pneumonia complicating pregnancy. Medicine 1998; 77: 15–67CrossRefGoogle Scholar
  18. 18.
    Saade GR. Human immunodeficiency virus (HIV)-related pulmonary complications in pregnancy. Semin Perinatol 1997; 21: 336–50PubMedCrossRefGoogle Scholar
  19. 19.
    Elewski BE. Superficial mycoses, dermatophytoses and selected dermatomycoses. In: Elewski BE, editor. Topics in clinical dermatology: cutaneous fungal infections. New York (NY): Igakin-Shoin, 1992: 12–68Google Scholar
  20. 20.
    Chow AW, Jewesson PJ. Pharmacokinetics and safety of antimicrobial agents during pregnancy. Rev Infect dis 1985; 7: 287–313PubMedCrossRefGoogle Scholar
  21. 21.
    King CT, Rogers PD, Cleary JD, et al. Antifungal therapy during pregnancy. Clin Infect Dis 1998; 27: 1151–60PubMedCrossRefGoogle Scholar
  22. 22.
    Lasher Jr JL. Therapeutic agents for dermatologic fungal diseases. In: Elewski B, editor. Topics in clinical dermatology: cutaneous fungal infections. Tokyo: Igaku-Shoin, 1992: 229–41Google Scholar
  23. 23.
    Frerich W, Gad B. The frequency of Candida infections in pregnancy and their treatment with clotrimazole. Curr Med Res Opin 1977; 4: 640–4PubMedCrossRefGoogle Scholar
  24. 24.
    Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997; 72: 253–6PubMedCrossRefGoogle Scholar
  25. 25.
    Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22: 336–40PubMedCrossRefGoogle Scholar
  26. 26.
    Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999; 19: 221–2PubMedCrossRefGoogle Scholar
  27. 27.
    Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996; 175: 1645–50PubMedCrossRefGoogle Scholar
  28. 28.
    Wallenburg HC, Wladimiroff JUB. Recurrence of vulvovaginal candidosis during pregnancy. Comparison of miconazole vs. nystatin treatment. Obstet Gynecol 1976; 48: 491–4PubMedGoogle Scholar
  29. 29.
    Lang WR, Stella JG, Bendrakan V. Nystatin vaginal tablets in the treatment of candidal vulvovaginitis. Obstet Gynecol 1965; 8: 364–7Google Scholar
  30. 30.
    Guidelines for treatment of sexually transmitted disease. MMWR Morb Mortal Wkly Rep 1998; 47 RR-1: 75–9Google Scholar
  31. 31.
    McNellis D, McLeod M, Lawson J, et al. Treatment of vulvovaginal candidiasis in pregnancy: a comparative study. Obstet Gynecol 1977; 50: 674–8PubMedGoogle Scholar
  32. 32.
    Weisberg M. Treatment of vaginal candidiasis in pregnant women. Clin Ther 1986; 8: 563–7PubMedGoogle Scholar
  33. 33.
    Higashide K, Kawaguchi C, Tomoda Y. Three-day clotrimazole therapy for vulvovaginal mycoses. J Int Med Res 1983; 11: 21–7PubMedGoogle Scholar
  34. 34.
    Haram K, Digranes A. Vulvovaginal candidiasis in pregnancy treated with clotrimazole. Acta Obstet Gynecol Scand 1978; 57: 453–5PubMedCrossRefGoogle Scholar
  35. 35.
    Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first trimester vaginitis drug therapy. Obstet Gynecol 1987; 69: 751–5PubMedGoogle Scholar
  36. 36.
    Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203–11PubMedCrossRefGoogle Scholar
  37. 37.
    Wiesinger EC, Mayerhofer S, Wenisch C, et al. Fluconazole in Candida albicans sepsis during pregnancy: case report and review of the literature. Infection 1996; 24: 263–6PubMedCrossRefGoogle Scholar
  38. 38.
    Vanderveen EE, Messenger AL, Voorhees JJ. Sporotrichosis in pregnancy. Cutis 1982; 30: 761–3PubMedGoogle Scholar
  39. 39.
    Bennett JE. Flucytoin. Ann Intern Med 1977; 86: 319–22Google Scholar
  40. 40.
    Chen CP, Wang K. Cryptococcal meningitis in pregnancy. Am J Perinatal 1996; 13: 35–6CrossRefGoogle Scholar
  41. 41.
    Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the aquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15–21PubMedCrossRefGoogle Scholar
  42. 42.
    Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30(4): 662–78PubMedCrossRefGoogle Scholar
  43. 43.
    Dean JL, Wolf JE, Ranzini AC, et al. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994; 18: 364–8PubMedCrossRefGoogle Scholar
  44. 44.
    Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. Adv Pharmacol 1997; 39: 143–89PubMedCrossRefGoogle Scholar
  45. 45.
    Tiboni GM. Second brachial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res Commun Chem Pathol Pharmacol 1993; 79: 381–4PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of Internal MedicineWayne State University School of Medicine, Detroit Medical Center, Harper HospitalDetroitUSA

Personalised recommendations